The lipid Metabolism of Zhibitai in liver dysfunction
Lingyun Chen
Abstract
Lingyun Chen
Abstract
Objective To analyze the lipid levels in liver damage. Methods 82 patients with liver damage were divided into the study group(41 patients)and control group(41 patients), the control group patients were given treatment of atorvastatin, while the study group patients were given treatment of Zhibitai, the lipid metabolism of the two groups were compared. Results In the study group,levels of TC(5.16±0.8)mmol/L,TG (1.90±0.08)mmol/L,LDL(2.03±0.11)mmol/L were significantly lower than before treatment TC(5.82±1.26)mmol/L(t=4.38,P<0.05),TG(2.16±0.85)mmol/L(t=6.37,P<0.05),LDL(3.67±0.09)mmol/L(t =6.42).The HDL level(1.39±0.26)mmol/L was significantly increased(0.86±0.21)mmol/L(t=7.52,P< 0.05)after 4 weeks treatment(P<0.05).The incidence of adverse events in the study group(7.3%)was significantly lower than the control group(17.1%)(P<0.05). Conclusion Zhibitai is safe and effective with use value in the treatment of liver dysfunction. Key words: Liver damage; Zhibitai; Lipid; Atorvastatin
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To analyze the lipid levels in liver damage. Methods 82 patients with liver damage were divided into the study group(41 patients)and control group(41 patients), the control group patients were given treatment of atorvastatin, while the study group patients were given treatment of Zhibitai, the lipid metabolism of the two groups were compared. Results In the study group,levels of TC(5.16±0.8)mmol/L,TG (1.90±0.08)mmol/L,LDL(2.03±0.11)mmol/L were significantly lower than before treatment TC(5.82±1.26)mmol/L(t=4.38,P<0.05),TG(2.16±0.85)mmol/L(t=6.37,P<0.05),LDL(3.67±0.09)mmol/L(t =6.42).The HDL level(1.39±0.26)mmol/L was significantly increased(0.86±0.21)mmol/L(t=7.52,P< 0.05)after 4 weeks treatment(P<0.05).The incidence of adverse events in the study group(7.3%)was significantly lower than the control group(17.1%)(P<0.05). Conclusion Zhibitai is safe and effective with use value in the treatment of liver dysfunction. Key words: Liver damage; Zhibitai; Lipid; Atorvastatin
Key concepts: Medicine, Internal medicine, Atorvastatin, Gastroenterology, Lipid metabolism, Incidence (geometry), Metabolism, Endocrinology